The U.S. Food and Drug Administration (FDA) has officially granted approval for ViiV Healthcare’s Tivicay PD (dolutegravir) to treat HIV-1 infection in pediatric patients weighing at least 2 kilograms, effectively removing the minimum age requirement for the medication. This regulatory milestone marks a significant shift in the treatment landscape for infants diagnosed with HIV, particularly those in their first month of life who previously faced a critical lack of age-appropriate therapeutic options. The dispersible tablet formulation, designed for ease of administration, represents the first second-generation integrase strand transfer inhibitor (INSTI) available for such a young and low-weight demographic.
A Landmark Regulatory Shift for Neonatal HIV Care
Prior to this approval, the clinical management of newborns with HIV was hampered by a restricted formulary. While the original Tivicay (dolutegravir) was approved in 2013 for adults and adolescents weighing at least 40 kg, the pediatric population—specifically those under the age of four weeks—remained underserved. A 2020 FDA action allowed the use of the dispersible Tivicay PD formulation for infants at least four weeks old and weighing at least 3 kg.
The new, expanded indication is a vital step forward, as it now covers neonates from birth, provided they meet the 2 kg (approximately 4.4 lbs) weight threshold. This change ensures that clinicians can initiate effective, potent antiretroviral therapy (ART) immediately following a diagnosis, rather than waiting for an infant to reach a higher age or weight milestone. Early initiation of treatment is universally recognized as the gold standard in pediatric HIV care to prevent rapid disease progression and improve long-term health outcomes.
Chronology of Clinical Development and Approval
The journey to this approval was rooted in extensive, multinational clinical research aimed at bridging the gap between adult and pediatric drug efficacy. The pivotal support for this FDA decision came from the NIH-funded IMPAACT 2023 study, a multicenter phase 1 clinical trial.
The study’s timeline involved a rigorous evaluation of pharmacokinetics, safety, and tolerability in 48 mother-infant pairs across clinical sites in South Africa, Thailand, and the United States. Key milestones in this research trajectory include:
- Initial Enrollment (2023-2024): The IMPAACT network successfully enrolled 48 infants exposed to HIV-1, ensuring a diverse demographic representation to validate the drug’s performance across different populations.
- Dosing and Monitoring (2024-2025): Newborns weighing at least 2 kg received Tivicay PD from birth for up to six weeks alongside standard-of-care antiretroviral regimens. Researchers conducted comprehensive 16-week follow-up assessments to monitor drug metabolism and adverse effects.
- CROI 2025 Presentation: Preliminary data from the chronic-dosing cohort, which included 15 infants, were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in 2025. These results demonstrated that infants weighing between 2.3 and 3.6 kg could successfully transition to a daily dosing regimen after an initial every-other-day schedule during the first two weeks of life.
- FDA Priority Review (2026): Leveraging the robust pharmacokinetic modeling and clinical trial results, the FDA granted the application Priority Review, acknowledging the urgent unmet medical need for neonates living with HIV.
Clinical Data and Pharmacological Findings
The clinical evidence supporting this approval indicates that dolutegravir performs reliably in neonates. According to FDA findings, the drug levels achieved in newborns were comparable to those observed in adults, where the drug is well-established as a highly effective antiviral agent.
The safety profile of Tivicay PD in this study was consistent with findings in older pediatric and adult populations, demonstrating that the medication is well-tolerated by the developing physiological systems of newborns. The ability to administer the drug in a dispersible form is crucial for this population, as it eliminates the challenges associated with administering large pills to infants, facilitating better adherence to complex treatment regimens.
Addressing the Global HIV Treatment Gap
The necessity for this approval is underscored by sobering statistics regarding untreated HIV in children. UNICEF reports indicate that roughly half of all infants living with HIV will succumb to the virus before their second birthday if they do not receive timely antiretroviral treatment. While perinatal transmission in the United States has been successfully minimized to less than 1% through rigorous prenatal care and prophylactic measures, the global burden remains significant.
For the fewer than 50 infants born with HIV annually in the U.S., as well as the thousands affected globally, the availability of a potent, once-daily, or age-adjusted dosing regimen like Tivicay PD is transformative. Dr. Diana F. Clarke, a professor at the Boston University School of Medicine and the lead investigator of the IMPAACT 2023 study, emphasized that the lack of study-backed options for newborns has historically been a major hurdle. This approval helps dismantle that barrier, allowing for earlier intervention that can suppress viral loads and potentially prevent the development of opportunistic infections.
Corporate Strategy and Market Implications
From a commercial perspective, the approval of Tivicay PD for this expanded indication provides a vital specialized niche for ViiV Healthcare, which is majority-owned by GSK. While the standalone Tivicay brand has seen sales plateau—with GSK reporting £1.323 billion in 2025 sales, reflecting a slight decline—the company’s broader HIV portfolio continues to thrive.
The growth of GSK’s HIV franchise, which reached £7.687 billion in 2025, is primarily driven by newer, long-acting, and combination therapies such as Dovato, Cabenuva, and Apretude. The expansion of the Tivicay PD label serves as an important strategic pillar, ensuring that the legacy dolutegravir platform remains relevant and medically necessary in the pediatric space, even as the company pivots toward long-acting injectable treatments.
Future Outlook and Scientific Implications
The FDA’s approval of Tivicay PD for newborns is not merely a regulatory administrative act; it represents a triumph of pediatric drug development. By utilizing pharmacokinetic modeling and multicenter international trials, ViiV Healthcare has provided a blueprint for how pharmaceutical companies can navigate the complexities of testing medications in highly vulnerable populations.
The implications of this development are threefold:
- Clinical Practice: Pediatricians and neonatologists now have an evidence-based tool to treat HIV from day one, which is expected to reduce morbidity and mortality among HIV-positive infants.
- Public Health: The ability to treat infants immediately upon diagnosis supports international goals to eliminate mother-to-child transmission and improve the quality of life for children living with HIV.
- Research Precedent: The successful use of the IMPAACT network to facilitate this study provides a framework for future research into other antiretroviral or opportunistic infection drugs that are currently unavailable for newborns.
As medical science continues to advance, the focus on "closing the gap" for pediatric populations remains a critical priority. With the introduction of this second-generation INSTI into the neonatal formulary, the medical community is now better equipped to manage one of the most challenging aspects of the global HIV epidemic. The integration of this treatment into standard clinical protocols will likely be the next phase in ensuring that the smallest patients receive the highest standard of care, regardless of their age or weight at birth.
